Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.

Woods KA, Camacho-Hübner C, Bergman RN, Barter D, Clark AJ, Savage MO

The Journal of clinical endocrinology and metabolism1 Apr 2000Cited by 77 (Europe PMC)

PMID10770174DOI10.1210/jcem.85.4.6495PepBankPUB-10770174

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanCase report or seriesEfficacy outcome
In a patient with IGF-I gene deletion, BMI increased from 17 to 18.6 kg/m2 on rhIGF-I.
In plain wordsIn a patient with IGF-I gene deletion, body mass index increased from baseline on rhIGF-I.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseBody mass index
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
40 microg/kg daily, increasing after 3 months to 80 microg/kg daily · 1 yrAs given in this study (human).
Measurements
Body mass index
17 kg/m2
before rhIGF-I therapy
Body mass index
18.6 kg/m2
on rhIGF-I therapy
Source sentences
Summary
On IGF-I therapy, body mass index increased from 17 kg/m2 to 18.6 kg/m2.
2 context sentences(design, population, supporting numbers)
Summary · context
We have recently reported a patient with a homozygous partial deletion of the insulin-like growth factor-I (IGF-I) gene, resulting in IGF-I deficiency, insulin resistance, and short stature.
Summary · context
We now report results of 1 yr of rhIGF-I therapy on body composition, bone mineral density (BMD), insulin sensitivity, and linear growth in this patient.
Report a problemFND-1077017401
02HumanCase report or seriesEfficacy outcome
In a patient with IGF-I gene deletion, body fat fell to 15.1% at 6 months, then rose to 21.8% at 12 months.
In plain wordsIn a patient with IGF-I gene deletion, body fat initially fell, then rose during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
MixedTotal body fat
Study
n = 1
Outcome group
Body composition · Metabolic and weight
Studied dose
40 microg/kg daily, increasing after 3 months to 80 microg/kg daily · 1 yrAs given in this study (human).
Measurements
Total body fat
19.9%
baseline
Total body fat
15.1%
6 months
Total body fat
21.8%
12 months
Source sentences
Summary
Body composition studies (dual-energy x-ray absorbtiometry) revealed an initial decrease in total body fat, from 19.9% at baseline to 15.1% at 6 months; but by 12 months of therapy, this had reversed, with an increase to 21.8%.
2 context sentences(design, population, supporting numbers)
Summary · context
We have recently reported a patient with a homozygous partial deletion of the insulin-like growth factor-I (IGF-I) gene, resulting in IGF-I deficiency, insulin resistance, and short stature.
Summary · context
We now report results of 1 yr of rhIGF-I therapy on body composition, bone mineral density (BMD), insulin sensitivity, and linear growth in this patient.
Report a problemFND-1077017402
03HumanCase report or seriesEfficacy outcome
In a patient with IGF-I gene deletion, rhIGF-I at 40 microg/kg daily increased insulin sensitivity to 2.06 x 10-4 min-l.
In plain wordsIn a patient with IGF-I gene deletion, lower-dose rhIGF-I improved insulin sensitivity from baseline.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseInsulin sensitivity at lower dose
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
40 microg/kg daily · 3 monthsAs given in this study (human).
Measurements
Insulin sensitivity (Si)
2.06 x 10-4 min-l
rhIGF-I 40 microg/kg x day
Insulin sensitivity (Si)
1.45 x 10-4 min-1 (microU/mL)
baseline before rhIGF-I therapy
Source sentences
Summary
rhIGF-I therapy resulted in a dose-related improvement of Si into the normal range (NR) (rhIGF-I dose: 40 microg/kg x day, Si = 2.06 x 10-4 min-l; rhIGF-I dose: 80 microg/kg x day, Si = 4.39 x 10-4 min-1).
Summary
Si, calculated using Bergman's minimal model, was substantially reduced at baseline at 1.45 x 10-4 min-1 (microU/mL) [normal value, 5.1 x 10-4 min 1 (lean adult male)].
2 context sentences(design, population, supporting numbers)
Summary · context
We have recently reported a patient with a homozygous partial deletion of the insulin-like growth factor-I (IGF-I) gene, resulting in IGF-I deficiency, insulin resistance, and short stature.
Summary · context
We now report results of 1 yr of rhIGF-I therapy on body composition, bone mineral density (BMD), insulin sensitivity, and linear growth in this patient.
Report a problemFND-1077017403
04HumanCase report or seriesEfficacy outcome
In a patient with IGF-I gene deletion, rhIGF-I at 80 microg/kg daily increased insulin sensitivity to 4.39 x 10-4 min-1.
In plain wordsIn a patient with IGF-I gene deletion, higher-dose rhIGF-I improved insulin sensitivity from baseline.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseInsulin sensitivity at higher dose
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
80 microg/kg daily · 1 yrAs given in this study (human).
Measurements
Insulin sensitivity (Si)
4.39 x 10-4 min-1
rhIGF-I 80 microg/kg x day
Insulin sensitivity (Si)
1.45 x 10-4 min-1 (microU/mL)
baseline before rhIGF-I therapy
Source sentences
Summary
rhIGF-I therapy resulted in a dose-related improvement of Si into the normal range (NR) (rhIGF-I dose: 40 microg/kg x day, Si = 2.06 x 10-4 min-l; rhIGF-I dose: 80 microg/kg x day, Si = 4.39 x 10-4 min-1).
Summary
Si, calculated using Bergman's minimal model, was substantially reduced at baseline at 1.45 x 10-4 min-1 (microU/mL) [normal value, 5.1 x 10-4 min 1 (lean adult male)].
2 context sentences(design, population, supporting numbers)
Summary · context
We have recently reported a patient with a homozygous partial deletion of the insulin-like growth factor-I (IGF-I) gene, resulting in IGF-I deficiency, insulin resistance, and short stature.
Summary · context
We now report results of 1 yr of rhIGF-I therapy on body composition, bone mineral density (BMD), insulin sensitivity, and linear growth in this patient.
Report a problemFND-1077017404
05HumanCase report or seriesEfficacy outcome
In a patient with IGF-I gene deletion, elevated acute insulin response to glucose fell dose-dependently during rhIGF-I treatment.
In plain wordsIn a patient with IGF-I gene deletion, insulin response to glucose decreased as the rhIGF-I dose increased.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseAcute insulin response to glucose
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
40 microg/kg daily, increasing after 3 months to 80 microg/kg daily · 1 yrAs given in this study (human).
Source sentences
Summary
Baseline reduction in Si was accompanied by elevated acute insulin response to glucose, which also fell in a dose-dependent manner.
2 context sentences(design, population, supporting numbers)
Summary · context
We have recently reported a patient with a homozygous partial deletion of the insulin-like growth factor-I (IGF-I) gene, resulting in IGF-I deficiency, insulin resistance, and short stature.
Summary · context
We now report results of 1 yr of rhIGF-I therapy on body composition, bone mineral density (BMD), insulin sensitivity, and linear growth in this patient.
Report a problemFND-1077017405
06HumanCase report or seriesEfficacy outcome
In a patient with IGF-I gene deletion, rhIGF-I increased bone mineral density by 17%.
In plain wordsIn a patient with IGF-I gene deletion, rhIGF-I increased bone mineral density from baseline.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseBone mineral density
Study
n = 1
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg/kg daily, increasing after 3 months to 80 microg/kg daily · 1 yrAs given in this study (human).
Measurements
Bone mineral density change
17%
on rhIGF-I therapy
Bone mineral density relative to age-matched controls
−4.88 SD
baseline before rhIGF-I therapy
Source sentences
Summary
rhIGF-I therapy increased BMD by 17% and bone mineral apparent density by 7%, indicating that IGF-I has a greater effect on bone growth than bone mineralization.
Summary
Baseline BMD was severely reduced when compared with age-matched controls (-4.88 SD); however, calculation of bone mineral apparent density indicated that the true reduction in BMD was minimal.
2 context sentences(design, population, supporting numbers)
Summary · context
We have recently reported a patient with a homozygous partial deletion of the insulin-like growth factor-I (IGF-I) gene, resulting in IGF-I deficiency, insulin resistance, and short stature.
Summary · context
We now report results of 1 yr of rhIGF-I therapy on body composition, bone mineral density (BMD), insulin sensitivity, and linear growth in this patient.
Report a problemFND-1077017406
07HumanCase report or seriesEfficacy outcome
In a patient with IGF-I gene deletion, rhIGF-I increased bone mineral apparent density by 7%.
In plain wordsIn a patient with IGF-I gene deletion, rhIGF-I increased estimated bone density after adjustment for bone size.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseBone mineral apparent density
Study
n = 1
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg/kg daily, increasing after 3 months to 80 microg/kg daily · 1 yrAs given in this study (human).
Measurements
Bone mineral apparent density change
7%
on rhIGF-I therapy
Source sentences
Summary
rhIGF-I therapy increased BMD by 17% and bone mineral apparent density by 7%, indicating that IGF-I has a greater effect on bone growth than bone mineralization.
2 context sentences(design, population, supporting numbers)
Summary · context
We have recently reported a patient with a homozygous partial deletion of the insulin-like growth factor-I (IGF-I) gene, resulting in IGF-I deficiency, insulin resistance, and short stature.
Summary · context
We now report results of 1 yr of rhIGF-I therapy on body composition, bone mineral density (BMD), insulin sensitivity, and linear growth in this patient.
Report a problemFND-1077017407
08HumanCase report or seriesEfficacy outcome
In a patient with IGF-I gene deletion, serum osteocalcin increased from 8.3 to 21.7 ng/mL after 6 months of rhIGF-I.
In plain wordsIn a patient with IGF-I gene deletion, the bone turnover marker osteocalcin increased during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseSerum osteocalcin
Study
n = 1
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg/kg daily, increasing after 3 months to 80 microg/kg daily · 6 monthsAs given in this study (human).
Measurements
Serum osteocalcin
8.3 ng/mL
pretreatment
Serum osteocalcin
21.7 ng/mL
after 6 months of rhIGF-I
Source sentences
Summary
Bone turnover markers also increased on rhIGF-I; mean serum osteocalcin: 8.3 ng/mL pretreatment, 21.7 ng/mL after 6 months of rhIGF-I (NR for adult male, 3.4-9.1 ng/mL);
2 context sentences(design, population, supporting numbers)
Summary · context
We have recently reported a patient with a homozygous partial deletion of the insulin-like growth factor-I (IGF-I) gene, resulting in IGF-I deficiency, insulin resistance, and short stature.
Summary · context
We now report results of 1 yr of rhIGF-I therapy on body composition, bone mineral density (BMD), insulin sensitivity, and linear growth in this patient.
Report a problemFND-1077017408
09HumanCase report or seriesEfficacy outcome
In a patient with IGF-I gene deletion, bone-specific alkaline phosphatase increased from 36.5 to 82.2 U/L after 6 months.
In plain wordsIn a patient with IGF-I gene deletion, bone-specific alkaline phosphatase increased during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseBone-specific alkaline phosphatase
Study
n = 1
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg/kg daily, increasing after 3 months to 80 microg/kg daily · 6 monthsAs given in this study (human).
Measurements
Bone specific alkaline phosphatase
36.5 U/L
pretreatment
Bone specific alkaline phosphatase
82.2 U/L
after 6 months of therapy
Source sentences
Summary
mean bone specific alkaline phosphatase: 36.5 U/L pretreatment, 82.2 U/L after 6 months of therapy (NR for adult male, 15-41).
2 context sentences(design, population, supporting numbers)
Summary · context
We have recently reported a patient with a homozygous partial deletion of the insulin-like growth factor-I (IGF-I) gene, resulting in IGF-I deficiency, insulin resistance, and short stature.
Summary · context
We now report results of 1 yr of rhIGF-I therapy on body composition, bone mineral density (BMD), insulin sensitivity, and linear growth in this patient.
Report a problemFND-1077017409
10HumanCase report or seriesEfficacy outcome
In a patient with IGF-I gene deletion, height velocity increased from 3.8 to 7.3 cm/yr on rhIGF-I.
In plain wordsIn a patient with IGF-I gene deletion, growth speed increased from baseline on rhIGF-I.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseHeight velocity
Study
n = 1
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 microg/kg.day · 1 yrAs given in this study (human).
Measurements
Height velocity
3.8 cm/yr
pretreatment
Height velocity
7.3 cm/yr
on 80 microg/kg.day rhIGF-I
Source sentences
Summary
Height velocity increased from 3.8 cm/yr pretreatment to 7.3 cm/yr on 80 microg/kg.day of rhIGF-I.
2 context sentences(design, population, supporting numbers)
Summary · context
We have recently reported a patient with a homozygous partial deletion of the insulin-like growth factor-I (IGF-I) gene, resulting in IGF-I deficiency, insulin resistance, and short stature.
Summary · context
We now report results of 1 yr of rhIGF-I therapy on body composition, bone mineral density (BMD), insulin sensitivity, and linear growth in this patient.
Report a problemFND-1077017410

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.